Ipratropiumbromid/Salbutamol "neutec"

Ipratropium bromide, the active ingredient in Ipratropiumbromid/Salbutamol \"neutec\", is a short‑acting muscarinic antagonist presented as an inhalation aerosol (metered‑dose inhaler) for inhalation use. Combined with salbutamol, a short‑acting β2‑agonist, the product provides bronchodilation for chronic obstructive pulmonary disease and rapid relief of asthma symptoms.

GNH USA supplies Ipratropiumbromid/Salbutamol \"neutec\" as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is available for export to multiple regions, ensuring quality and consistency across shipments.

Ipratropium bromide/salbutamol inhalation aerosol is used to manage airway obstruction in chronic respiratory diseases.

- Chronic obstructive pulmonary disease (COPD): improves lung function and reduces breathlessness during stable disease and exacerbations. - Asthma: delivers fast‑acting bronchodilation to relieve acute symptoms or exercise‑induced bronchospasm. - Acute bronchospasm: provides rapid airway opening when sudden constriction occurs.

The inhaler may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Throat irritation or dryness - Cough - Tremor of the hands or fingers - Headache - Palpitations - Dry mouth

Serious or Rare Side Effects: - Paradoxical bronchospasm - Significant tachycardia or arrhythmia - Angioedema or severe allergic reaction - Hyperglycaemia in susceptible individuals - Acute hypertension - Severe hypokalaemia

Use of this combination inhaler requires careful clinical assessment and monitoring.

- Assess patient history: check for hypersensitivity to anticholinergics or β2‑agonists. - Monitor cardiovascular status: use cautiously in patients with tachyarrhythmias or coronary disease. - Avoid excessive dosing: follow prescriber instructions to prevent systemic anticholinergic or adrenergic effects. - Use with caution in patients with narrow‑angle glaucoma, urinary retention, or prostatic hypertrophy. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and heat, store in original container.

Drug interactions may modify the therapeutic effect or increase adverse risk.

Major Interactions (Avoid): - Beta‑blockers: may blunt bronchodilator response. - Monoamine oxidase inhibitors: can increase cardiovascular stimulation. - Diuretics: may potentiate hypokalaemia when combined with salbutamol.

Moderate Interactions (Monitor Closely):\n- Theophylline: additive risk of tachycardia and tremor. - Inhaled corticosteroids: may enhance bronchodilator efficacy. - Other anticholinergic agents: additive anticholinergic load may increase dry mouth or urinary retention.